Physician profile
Nicole L Allison
NPI 1285660670
$14,158.48
in general payments reported to CMS, 2019-2025
24 companies · $2,214 in 2025
The $2,214 reported for 2025 was more than what 97% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,140 · 2022: $3,143 · 2023: $3,002 · 2024: $2,659 · 2025: $2,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,856 · Education: $19.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,855.57 |
| Education | $19.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,832.64 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $1,508.83 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $1,474.50 | 2021-2025 | Rexulti, Abilify Mycite, Nuedexta |
| Alkermes, INC. | $1,118.32 | 2021-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $1,041.97 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $699.01 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $653.15 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $595.31 | 2021-2024 | Rexulti |
| Corium, LLC | $563.23 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $520.85 | 2021-2022 | |
| Axsome Therapeutics, INC. | $514.33 | 2023-2025 | Auvelity, Sunosi |
| Teva Pharmaceuticals USA, INC. | $477.68 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Tris Pharma INC | $312.37 | 2022-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $251.25 | 2021-2025 | Spravato |
| Neos Therapeutics, Lp | $172.02 | 2021-2024 | Adzenys Xr-Odt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $107.94 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $79.13 | 2022-2025 | Wellbutrin, Aplenzin |
| Eisai INC. | $66.57 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $57.27 | 2022-2025 | Qelbree, Qelbree |
| Almatica Pharma LLC | $32.13 | 2022 | |
| Ironshore Pharmaceuticals INC. | $24.34 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.33 | 2024 | Rexulti |
| Invivyd INC | $19.56 | 2025 | Pemgarda |
| Tonix Medicines, INC. | $14.75 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Allison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.